Prime Medicine upgraded by Citigroup with a new price target
$PRME
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup upgraded Prime Medicine from Neutral to Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $1.50 | Buy → Neutral | Citigroup |
| 5/20/2025 | Overweight → Neutral | Analyst | |
| 5/20/2025 | Buy → Neutral | H.C. Wainwright | |
| 12/10/2024 | $10.00 | Mkt Outperform | JMP Securities |
| 5/20/2024 | $10.00 | Buy | H.C. Wainwright |
| 5/16/2024 | $10.00 | Neutral → Buy | Citigroup |
| 4/22/2024 | $17.00 | Buy | Chardan Capital Markets |
| 4/8/2024 | Buy | TD Cowen |